Haloperidol depot spc

Aripiprazole's mechanism of action is different from those of the other FDA-approved atypical antipsychotics (., clozapine , olanzapine , quetiapine , ziprasidone , and risperidone ). [44] [48] [49] [50] [51] [52] [53] [54] Rather than acting as a pure antagonist of the dopamine D 2 receptor , aripiprazole shows functional selectivity at the D 2 receptor, acting as a silent antagonist of some subpopulations of D 2 receptors but as a high-efficacy partial agonist ( intrinsic activity = 75%) of other D 2 -receptor subpopulations. [44] It appears to show predominantly antagonist activity on postsynaptic D 2 receptors and partial agonist activity on presynaptic D 2 receptors. [55] Aripiprazole is also a partial agonist of the D 3 receptor . [44] In healthy human volunteers, D 2 and D 3 receptor occupancy levels are high, with average levels ranging between approximately 71% at 2 mg/day to approximately 96% at 40 mg/day. [56] [57] Most atypical antipsychotics bind preferentially to extrastriatal receptors, but aripiprazole appears to be less preferential in this regard, as binding rates are high throughout the brain. [58]

Haloperidol depot spc

haloperidol depot spc

Media: